利培酮合并氯氮平治疗难治性精神分裂症的对照研究

目的　探讨利培酮合并氯氮平治疗难治性精神分裂症的疗效及副作用。方法　将本院 98例难治性精神分裂症患者按病期病型配对分成氯氮平组 (A组 )和利培酮组 (B组 )及 2药联用组 (AB组 ) ,用 PANSS及 TESS评定疗效及副作用。结果　 3组 8周疗效相似 ,有效率 A组为 61 .8% ,B组为 60 % ,AB组为 62 .5 % ,(P>0 .0 5 )。治疗 4周时 AB组疗效较单用组佳。A组、AB组对阳性症状起效较快。AB组副作用比单用组少。结论　适宜剂量的利培酮与氯氮平联用治疗难治性精神分裂症安全有效 ,副作用少。利培酮与氯氮平治疗难治性精神分裂症的起效时间较以往报告的要早

A Control Study of Risperidone and Clozapine Combination for the Treatment of Refractory Schizophrenia

Objective To explore the efficacy of risperidone and clozapine combination for the treatment of refractory schizophrenia.Method 98 cases of refractory schizophrenic patients matched in duration and subtypes were randomly assigned to three groups(A,B and AB)which received clozapine,risperidone and a combination of both medicaments respectively for 12 weeks.Efficacy and side effects were blindly assessed with PANSS and TESS.Results There was no significant difference in the effective rates among group A(61.8%),B(60%)and AB(62.5%)after 8 weeks of treatment(P>0.05).Efficacy of group AB was superior to that of the other two groups at the end of 4 weeks(P<0.05).Group A and AB produced a shortening of the treatment response latency on positive symptoms.Side effects were minimal for group AB than other two groups.Conclusion An appropriate combination of clozapine and risperidone is safe and effective for refractory schizophrenia and produces fewer side effects.Efficacy appears earlier than previous reports.